Kevin John Gaskin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kevin John Gaskin has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Aleixo M. Muise
Department of Paediatrics, Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children University of Toronto Toronto Ontario Canada
1 shared publication - Baroukh Maurice Assael
Scientific Advisor, Adult Cystic Fibrosis Center, University of Milano Medical School, Milano, Italy
1 shared publication - Brigitte Santner-Nanan
Charles Perkins Centre Nepean, Sydney Medical School Nepean, The University of Sydney, Sydney, NSW 2747, Australia
1 shared publication Caron S. Blumenthal
Women's and Newborn Health, Westmead Hospital, NSW 2145, Australia
1 shared publication- Cheng Hiang Lee
Nepean Clinical School, the University of Sydney, Kingswood, Australia
1 shared publication - Dmitry Shishmarev
AJohn Curtin School of Medical Research, Australian National University, Canberra, ACT 2601, Australia
1 shared publication
Latest Publications
- 1 May 2020
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 19 (3) , 455-459
Occurrence, outcomes and predictors of portal hypertension in cystic fibrosis: A longitudinal prospective birth cohort study
- 1 May 2020
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 19 (3) , 455-459
Occurrence, outcomes and predictors of portal hypertension in cystic fibrosis: A longitudinal prospective birth cohort study
- 1 November 2017
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 16 (6) , 763-770
Bile salt stimulated lipase: Inhibition by phospholipids and relief by phospholipase A2
- 1 November 2017
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 16 (6) , 763-770
Bile salt stimulated lipase: Inhibition by phospholipids and relief by phospholipase A2
- 1 November 2014
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 8 (11) , 1551-1556
Novel de novo mutations of the interleukin-10 receptor gene lead to infantile onset inflammatory bowel disease
Defects in the interleukin 10 (IL-10) signalling pathway have been shown to cause very early onset inflammatory bowel disease (IBD). We report a patient with severe infantile-onset IBD with a compound heterozygous IL-10 receptor alpha subunit (IL-10RA) mutation, one of which was paternally-inherited and the other occurring de novo. Deep sequencing of IL-10, IL-10RA and IL-10 receptor beta subunit (IL-10RB) were performed. Peripheral blood mononuclear cell (PBMC) surface expression of IL-10RA was analysed by flow cytometry. IL-10 signalling pathway was examined by measuring phosphorylated STAT3 in PBMC cultured in the presence of IL-6 or IL-10. We identified a missense mutation in exon 4 of IL-10RA (c.583T>C) in one allele and a nonsense mutation in exon 7 of IL-10RA (c.1368G>T) in the other allele. Neither mutation has been reported previously. The patient has functional IL-10RA deficiency despite normal IL-10RA expression. This represents the first case report of a de novo mutation of IL-10RA that is associated with very early onset severe IBD. Therefore, IL-10 pathway defect should be considered in patients with infantile-onset IBD even if the parents are non-consanguineous.
- 1 November 2014
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 8 (11) , 1551-1556
Novel de novo mutations of the interleukin-10 receptor gene lead to infantile onset inflammatory bowel disease
Defects in the interleukin 10 (IL-10) signalling pathway have been shown to cause very early onset inflammatory bowel disease (IBD). We report a patient with severe infantile-onset IBD with a compound heterozygous IL-10 receptor alpha subunit (IL-10RA) mutation, one of which was paternally-inherited and the other occurring de novo. Deep sequencing of IL-10, IL-10RA and IL-10 receptor beta subunit (IL-10RB) were performed. Peripheral blood mononuclear cell (PBMC) surface expression of IL-10RA was analysed by flow cytometry. IL-10 signalling pathway was examined by measuring phosphorylated STAT3 in PBMC cultured in the presence of IL-6 or IL-10. We identified a missense mutation in exon 4 of IL-10RA (c.583T>C) in one allele and a nonsense mutation in exon 7 of IL-10RA (c.1368G>T) in the other allele. Neither mutation has been reported previously. The patient has functional IL-10RA deficiency despite normal IL-10RA expression. This represents the first case report of a de novo mutation of IL-10RA that is associated with very early onset severe IBD. Therefore, IL-10 pathway defect should be considered in patients with infantile-onset IBD even if the parents are non-consanguineous.
- 1 March 2014
- Published by Elsevier in Paediatric Respiratory Reviews
- Vol. 15 (1) , 69-74
Liver Disease in Cystic Fibrosis
- 1 March 2014
- Published by Elsevier in Paediatric Respiratory Reviews
- Vol. 15 (1) , 69-74
Liver Disease in Cystic Fibrosis
- 6 March 2013
- Published by Springer Nature in European Journal of Clinical Nutrition
- Vol. 67 (5) , 558-564
Nutritional care in children with cystic fibrosis: are our patients becoming better?
Over the last 30 years, major advances have occurred in our understanding of the disorder cystic fibrosis (CF) with the discoveries of the underlying chloride transport defect and the 'CF gene', the CF transmembrane conductance regulator gene. Equally important from a clinical and patient perspective are the improvements in median survival from less than 10 to 20 years prior to 1980, approaching 30 years during the 1980s and over 45 years more recently. Improved antibiotic regimens and lung clearance therapy contributed to the enhanced survival, but a key factor accredited as adding a further 10 years to the median survival was improving and then maintaining normal growth and nutrition. In the main, the latter were achieved by adherence to a 'high-fat high-energy' diet rather than the advocated virtually universal policy of the 'low fat', which was associated with wasting and linear growth failure. The high-fat diet in conjunction with better control of malabsorption due to microspheric pancreatic enzyme replacement therapy, attention to adequate fat-soluble vitamin supplementation and newborn screening has ensured that at least 80-90% of children with CF will achieve better health and survival through their adult years.
- 6 March 2013
- Published by Springer Nature in European Journal of Clinical Nutrition
- Vol. 67 (5) , 558-564
Nutritional care in children with cystic fibrosis: are our patients becoming better?
Over the last 30 years, major advances have occurred in our understanding of the disorder cystic fibrosis (CF) with the discoveries of the underlying chloride transport defect and the 'CF gene', the CF transmembrane conductance regulator gene. Equally important from a clinical and patient perspective are the improvements in median survival from less than 10 to 20 years prior to 1980, approaching 30 years during the 1980s and over 45 years more recently. Improved antibiotic regimens and lung clearance therapy contributed to the enhanced survival, but a key factor accredited as adding a further 10 years to the median survival was improving and then maintaining normal growth and nutrition. In the main, the latter were achieved by adherence to a 'high-fat high-energy' diet rather than the advocated virtually universal policy of the 'low fat', which was associated with wasting and linear growth failure. The high-fat diet in conjunction with better control of malabsorption due to microspheric pancreatic enzyme replacement therapy, attention to adequate fat-soluble vitamin supplementation and newborn screening has ensured that at least 80-90% of children with CF will achieve better health and survival through their adult years.